Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 300 participants.

Also called NCT01351636

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 300 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01351636
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01351636. Randomized; no masking; primary purpose treatment. Start 2011-04 (actual); primary completion 2018-10-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients
Acronym
AHOCEP
Intervention (Drug)
Arotinolol Hydrochloride
Intervention (Drug)
Non arotinolol group
Lead sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01351636
Content hash
ad173f3e87fe98a4c63754b02b845057e34c83ac193fe220ad2ffac3c612fdcb